Potentiation of Hydroxyurea Cytotoxicity by Iron-Chelating Agent in Murine Tumor Models in vitro

K. Satyamoorthy, M. P. Chitnis, S. G. Pradhan

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    The biochemical modulation of tumor cell response to increase the cytotoxicity of Hydroxyurea (HU), directed at the ribonucleotide reductase enzyme, has been studied in in vitro. Mice bearing ascites tumor models such as L1210 leukemia, Sarcoma 180 (S180) and Ehrlich ascites tumor (EAT) were employed in this study. The cytotoxicity of HU alone at various concentrations was dose dependent and showed the following order of sensitivity: L1210 > EAT > S180. The hydrophobic iron-chelating agent 2,2bipyridyl significantly potentiated the antitumor activity of HU in all the murine tumor models studied. In contrast, hydrophilic iron-chelator, Desferal, did not show any cytotoxicity when combined with HU. The present study demonstrated the factors influencing the amelioration of HU cytotoxicity and possible therapeutic use of ironchelating agents alone and with HU for better therapeutic results in clinics.

    Original languageEnglish
    Pages (from-to)173-182
    Number of pages10
    JournalCancer Drug Delivery
    Volume3
    Issue number3
    DOIs
    Publication statusPublished - 1986

    Fingerprint

    Iron Chelating Agents
    Hydroxyurea
    Sarcoma 180
    Ehrlich Tumor Carcinoma
    Neoplasms
    Ribonucleotide Reductases
    Leukemia L1210
    Deferoxamine
    Therapeutic Uses
    Chelating Agents
    Ascites
    In Vitro Techniques
    Iron
    Enzymes

    All Science Journal Classification (ASJC) codes

    • Pharmacology
    • Cancer Research

    Cite this

    @article{ff67ae63961a43d4a5f1baf7becdb5da,
    title = "Potentiation of Hydroxyurea Cytotoxicity by Iron-Chelating Agent in Murine Tumor Models in vitro",
    abstract = "The biochemical modulation of tumor cell response to increase the cytotoxicity of Hydroxyurea (HU), directed at the ribonucleotide reductase enzyme, has been studied in in vitro. Mice bearing ascites tumor models such as L1210 leukemia, Sarcoma 180 (S180) and Ehrlich ascites tumor (EAT) were employed in this study. The cytotoxicity of HU alone at various concentrations was dose dependent and showed the following order of sensitivity: L1210 > EAT > S180. The hydrophobic iron-chelating agent 2,2bipyridyl significantly potentiated the antitumor activity of HU in all the murine tumor models studied. In contrast, hydrophilic iron-chelator, Desferal, did not show any cytotoxicity when combined with HU. The present study demonstrated the factors influencing the amelioration of HU cytotoxicity and possible therapeutic use of ironchelating agents alone and with HU for better therapeutic results in clinics.",
    author = "K. Satyamoorthy and Chitnis, {M. P.} and Pradhan, {S. G.}",
    year = "1986",
    doi = "10.1089/cdd.1986.3.173",
    language = "English",
    volume = "3",
    pages = "173--182",
    journal = "Cancer Biotherapy and Radiopharmaceuticals",
    issn = "1084-9785",
    publisher = "Mary Ann Liebert Inc.",
    number = "3",

    }

    Potentiation of Hydroxyurea Cytotoxicity by Iron-Chelating Agent in Murine Tumor Models in vitro. / Satyamoorthy, K.; Chitnis, M. P.; Pradhan, S. G.

    In: Cancer Drug Delivery, Vol. 3, No. 3, 1986, p. 173-182.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Potentiation of Hydroxyurea Cytotoxicity by Iron-Chelating Agent in Murine Tumor Models in vitro

    AU - Satyamoorthy, K.

    AU - Chitnis, M. P.

    AU - Pradhan, S. G.

    PY - 1986

    Y1 - 1986

    N2 - The biochemical modulation of tumor cell response to increase the cytotoxicity of Hydroxyurea (HU), directed at the ribonucleotide reductase enzyme, has been studied in in vitro. Mice bearing ascites tumor models such as L1210 leukemia, Sarcoma 180 (S180) and Ehrlich ascites tumor (EAT) were employed in this study. The cytotoxicity of HU alone at various concentrations was dose dependent and showed the following order of sensitivity: L1210 > EAT > S180. The hydrophobic iron-chelating agent 2,2bipyridyl significantly potentiated the antitumor activity of HU in all the murine tumor models studied. In contrast, hydrophilic iron-chelator, Desferal, did not show any cytotoxicity when combined with HU. The present study demonstrated the factors influencing the amelioration of HU cytotoxicity and possible therapeutic use of ironchelating agents alone and with HU for better therapeutic results in clinics.

    AB - The biochemical modulation of tumor cell response to increase the cytotoxicity of Hydroxyurea (HU), directed at the ribonucleotide reductase enzyme, has been studied in in vitro. Mice bearing ascites tumor models such as L1210 leukemia, Sarcoma 180 (S180) and Ehrlich ascites tumor (EAT) were employed in this study. The cytotoxicity of HU alone at various concentrations was dose dependent and showed the following order of sensitivity: L1210 > EAT > S180. The hydrophobic iron-chelating agent 2,2bipyridyl significantly potentiated the antitumor activity of HU in all the murine tumor models studied. In contrast, hydrophilic iron-chelator, Desferal, did not show any cytotoxicity when combined with HU. The present study demonstrated the factors influencing the amelioration of HU cytotoxicity and possible therapeutic use of ironchelating agents alone and with HU for better therapeutic results in clinics.

    UR - http://www.scopus.com/inward/record.url?scp=0023022547&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0023022547&partnerID=8YFLogxK

    U2 - 10.1089/cdd.1986.3.173

    DO - 10.1089/cdd.1986.3.173

    M3 - Article

    C2 - 3779602

    AN - SCOPUS:0023022547

    VL - 3

    SP - 173

    EP - 182

    JO - Cancer Biotherapy and Radiopharmaceuticals

    JF - Cancer Biotherapy and Radiopharmaceuticals

    SN - 1084-9785

    IS - 3

    ER -